Health · Cardiology · ✓ 2 outlets · second drug and trial details unconfirmed

Full Data Show Heart Drug Pelacarsen No Better Than Placebo as a Second Drug Is Also Reported to Fail

Full results for heart drugs were released on Saturday, Nov. 7. Pelacarsen, a drug aimed at an inherited heart-disease risk, was no better than a placebo on every measure. A promising cholesterol drug was also reported to have failed to prevent heart attacks or stroke; details of that trial have not been confirmed. Cardiologists had held high hopes for the drugs. A placebo is an inactive treatment given to a comparison group. Researchers are asking whether the studies were designed poorly or whether the underlying ideas about heart disease were wrong.

These drugs were meant to treat risk that statins and other common medicines do not address, so a clean failure removes a hoped-for option for patients with inherited risk. It also tests the idea that lowering a particular blood marker will lower heart attacks, which shapes what companies develop next.

If you or a relative have an inherited heart risk, nothing changes today: these drugs were not available to patients, and current medicines remain the standard. Ask a cardiologist before changing anything, and treat headlines about future drugs with caution until results are in.

The full data released Saturday show pelacarsen no better than placebo on every measure, so the trial found no benefit for patients.

Researchers are asking whether the trial designs or the underlying ideas about heart disease were at fault; that question has not been answered, and details of the second drug's trial are unconfirmed.

Confirmed: full data released Saturday show no benefit over placebo. Not confirmed: details of the second drug, exact numbers and the makers' plans. Watch for the companies' statements and any analysis of subgroups.

DailyDrop U.S. No. 34 · November 7, 2026 · Evening

Read today’s front page →